Chronic
Inflammatory Demyelinating polyneuropathy (CIDP) is a rare
neurological disorder which causes paralysis (impairment of sensory
function in limbs). It occurs due to the inflammation of nerve roots,
peripheral nerves, and destruction of the fatty protective covering
(myelin sheath) over the nerves. It slows down the transmission of
nerve signals, thus leading to destruction of nerve fibers. It can be
treated with corticosteroids or in combination with an
immunosuppressant, plasma exchange, and intravenous immunoglobulin
therapy.
Request
a Sample of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/2609
Global
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment
Market Drivers
Increasing
drug approvals by regulatory authorities is expected to boost the
global chronic inflammatory demyelinating polyneuropathy (CIDP)
treatment market growth. For instance, in March 2017, CSL Behring
received U.S. Food and Drug Administration (FDA) approval for
Privigen, an immunoglobulin therapy for the treatment of chronic
inflammatory demyelinating polyneuropathy (CIDP) disorder. 207
patients were treated with Privigen for 13 weeks and 73% out of these
207 patients responded to it in clinical trials. Furthermore, in
March 2018, CSL Behring received U.S. FDA approval for Hizentra,
which is a type of subcutaneous immunoglobulin therapy that prevents
relapsing neuromuscular disability. It offers a convenient treatment
type, in which patients can infuse themselves. The approval was based
on the phase III results of the clinical trial. These factors are
expected to propel the global chronic inflammatory demyelinating
polyneuropathy (CIDP) treatment market growth.
Global
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment
Market Regional Analysis
North
America is expected to hold a dominant position in the global chronic
inflammatory demyelinating polyneuropathy (CIDP) treatment market.
Factors such as initiatives from governments and other organizations
are expected to have an influence on the global chronic inflammatory
demyelinating polyneuropathy (CIDP) treatment market growth. For
instance, in April 2019, Guillain-Barre syndrome & Chronic
Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) international
foundation announced that it is going to celebrate May as GBS | CIDP
awareness month. They plan to create awareness about the foundation’s
legislative initiatives for CIDP patients through social media and
campaigns. The initiative is for creating a bill which includes the
establishment of the Medicare Part B Home Infusion Demonstration
Project, and increase in funds for treatment of CIDP patients. These
factors are expected to have a positive impact on the global chronic
inflammatory demyelinating polyneuropathy (CIDP) treatment market
growth.
Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Key
Players
Some
of the major players operating in the global chronic inflammatory
demyelinating polyneuropathy (CIDP) treatment market include CSL
Behring, Kedrion S.p.A., Takeda Pharmaceutical Co. Ltd., Shire Plc.,
GeNeuro SA ,Baxter International Inc., Octapharma AG and Grifols
S.A., Teijin Pharma Ltd. and Nihon Pharmaceutical Co. Ltd.
Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) treatment Market
Taxonomy
The
global chronic inflammatory demyelinating polyneuropathy (CIDP)
treatment market is segmented by treatment type, distribution channel
and regions.
By
Treatment Type
-
Intravenous immunoglobulin therapy
-
Privigen
-
Hizentra
-
Gamunex-C
-
Tegeline
-
Others
-
Corticosteroids
-
Others
By
Distribution Channel
-
Hospital pharmacies
-
Retail pharmacies
-
Online pharmacies
Browse
In-Depth Analysis Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/chronic-inflammatory-demyelinating-polyneuropathy-cidp-treatment-market-2609
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment